I discussed the N of 1 trial last month, on the nocebo effect of statins and how they can affect our ability to take statins.
On its heels, comes a paper by Jungyeon Moon, Robert Sedgh and Cynthia Jackevicius, that also looks at this nocebo effect a little differently, by retrospectively examining the reported adverse events in the FDA Adverse Reporting System database from 2010 to 2019 .
This post is free to read, but you will need to subscribe with your email ID to read the rest of the post.
This Content Is for Members
Already have an account? Log in